Endologix to Present at the Canaccord Genuity 35th Annual Growth Conference

20:00 EDT 9 Aug 2015 | Globe Newswire

IRVINE, Calif., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq: ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Bob Mitchell, President, is scheduled to present at the Canaccord Genuity 35th Annual Growth Conference in Boston, MA.

Event: Canaccord Genuity 35th Annual Growth Conference
Date: Wednesday, August 12, 2015
Time: 2:00 pm ET / 11:00 am PT

An audio webcast of the Company's presentation at the conferencewill be available by visiting the investor relations section of Endologix's website at A replay of the presentation will be available for 30 days.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. Endologix's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at

         Endologix, Inc.
         John McDermott, CEO
         Shelley Thunen, CFO
         (949) 595-7200
         The Ruth Group
         Nick Laudico (646) 536-7030
         Zack Kubow (646) 536-7020

More From BioPortfolio on "Endologix to Present at the Canaccord Genuity 35th Annual Growth Conference"

Quick Search


Relevant Topic

Acute Coronary Syndromes ACS
Acute Coronary Syndromes (ACS) is an umbrella term for situations where the blood supplied to the heart muscle is suddenly blocked. Treatment for acute coronary syndrome includes medicines and a procedure known as angioplasty, during which doctors inflat...